Osimertinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Osimertinib and local guidelines before prescribing.

Tyrosine kinase inhibitor

Mechanism

Third-generation EGFR tyrosine kinase inhibitor.

Uses

EGFR-mutant non-small-cell lung cancer.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Rash, diarrhoea, interstitial lung disease, QT prolongation, cardiomyopathy.

Interactions

CYP3A4 inducers reduce levels.

Contraindications and cautions

Interstitial lung disease

Monitoring

ECG, LVEF, FBC

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Caution in severe renal or hepatic impairment

Overdose and reversal

Supportive

Special advice

Check LVEF and QT; stop if ILD.

More from the textbook: uses, cautions and other points
Where it is discussed in the book